Internal Medicine, Vascular Medicine and Pneumology Department, Brest Teaching Hospital, Brest, France; Inserm, UMR 1304 (GETBO), Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France.
Inserm, UMR 1304 (GETBO), Western Brittany Thrombosis Study Group, Western Brittany University, Brest, France; Cardiology Department, Brest Teaching Hospital, Brest, France.
Thromb Res. 2022 Jun;214:93-105. doi: 10.1016/j.thromres.2022.04.016. Epub 2022 Apr 29.
The increased risk of arterial thrombotic (ATE) after VTE, particularly when they are unprovoked or cancer-associated has been established. However, the risk factors of ATE after these VTE remain unclear.
Using cause-specific hazard regression models, we determined risk factors of ATE (myocardial infarction, ischemic stroke, acute limb ischemia, digestive tract ischemia, or renal ischemia) in 2242 patients with unprovoked VTE and in 914 patients with cancer-associated VTE from a multi-center prospective cohort.
Of patients with unprovoked-VTE, 174 developed ATE (7.8%, incidence: 1.26 per 100 patient-years) during follow-up (median: 68 months). Among patients with cancer-associated VTE, 57 developed ATE (6.2%, incidence: 1.98 per 100 patient-years) during follow-up (median: 30 months). After multivariable analysis, the identified risk factors of ATE in patients with unprovoked-VTE were age > 65 years (vs. <50 years, HR 2.59, 95% CI: 1.56-4.29), past history of symptomatic atherosclerosis (HR 2.11, 95% CI: 1.40-3.19), and treatment with low molecule weight heparin (vs. vitamin K antagonists, HR: 2.26, 95% CI: 1.13-4.52). In patients with cancer-associated VTE, the identified risk factors of ATE were: past history of symptomatic atherosclerosis (HR: 3.13, 95% CI: 1.72-5.67), and ongoing anticoagulation at the diagnosis of VTE (HR: 2.77, 95% CI: 1.07-7.22).
The risk of ATE after unprovoked VTE and after cancer-associated VTE, is determined by some classic cardiovascular risk factors and appears to be influenced by anticoagulant treatment introduced for VTE, as well as the presence or absence of ongoing anticoagulation at the diagnosis of VTE.
静脉血栓栓塞症(VTE)后动脉血栓栓塞(ATE)的风险增加已得到证实,尤其是在无诱因或与癌症相关的情况下。然而,这些 VTE 后发生 ATE 的危险因素仍不清楚。
我们使用基于病因的危险比回归模型,在多中心前瞻性队列中,确定了 2242 例无诱因 VTE 患者和 914 例癌症相关 VTE 患者中 ATE(心肌梗死、缺血性脑卒中、急性肢体缺血、消化道缺血或肾缺血)的危险因素。
在无诱因 VTE 患者中,174 例(7.8%,发生率:1.26/100 患者-年)在随访期间(中位:68 个月)发生 ATE。在癌症相关 VTE 患者中,57 例(6.2%,发生率:1.98/100 患者-年)在随访期间(中位:30 个月)发生 ATE。多变量分析后,无诱因 VTE 患者 ATE 的危险因素包括年龄>65 岁(<50 岁,HR 2.59,95%CI:1.56-4.29)、有症状动脉粥样硬化病史(HR 2.11,95%CI:1.40-3.19)和低分子肝素治疗(与维生素 K 拮抗剂相比,HR:2.26,95%CI:1.13-4.52)。在癌症相关 VTE 患者中,ATE 的危险因素包括:有症状动脉粥样硬化病史(HR:3.13,95%CI:1.72-5.67)和 VTE 诊断时持续抗凝治疗(HR:2.77,95%CI:1.07-7.22)。
无诱因 VTE 和癌症相关 VTE 后发生 ATE 的风险取决于一些经典的心血管危险因素,并且似乎受到 VTE 治疗中引入的抗凝治疗以及 VTE 诊断时是否存在持续抗凝治疗的影响。